Enzo Biochem Net Income 2010-2023 | ENZ
Enzo Biochem net income from 2010 to 2023. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Enzo Biochem Annual Net Income
(Millions of US $) |
| 2022 |
$-18 |
| 2021 |
$8 |
| 2020 |
$-29 |
| 2019 |
$2 |
| 2018 |
$-10 |
| 2017 |
$-3 |
| 2016 |
$45 |
| 2015 |
$-2 |
| 2014 |
$-10 |
| 2013 |
$-18 |
| 2012 |
$-39 |
| 2011 |
$-13 |
| 2010 |
$-22 |
| 2009 |
$-24 |
Enzo Biochem Quarterly Net Income
(Millions of US $) |
| 2023-01-31 |
$-11 |
| 2022-10-31 |
$-11 |
| 2022-07-31 |
$-8 |
| 2022-04-30 |
$-5 |
| 2022-01-31 |
$-3 |
| 2021-10-31 |
$-2 |
| 2021-07-31 |
$3 |
| 2021-04-30 |
$2 |
| 2021-01-31 |
$2 |
| 2020-10-31 |
$0 |
| 2020-07-31 |
$-3 |
| 2020-04-30 |
$-10 |
| 2020-01-31 |
$-8 |
| 2019-10-31 |
$-8 |
| 2019-07-31 |
$-5 |
| 2019-04-30 |
$22 |
| 2019-01-31 |
$-8 |
| 2018-10-31 |
$-6 |
| 2018-07-31 |
$-6 |
| 2018-04-30 |
$-3 |
| 2018-01-31 |
$-1 |
| 2017-10-31 |
$-1 |
| 2017-07-31 |
$0 |
| 2017-04-30 |
$-0 |
| 2017-01-31 |
$-1 |
| 2016-10-31 |
$-1 |
| 2016-07-31 |
$36 |
| 2016-04-30 |
$-2 |
| 2016-01-31 |
$7 |
| 2015-10-31 |
$4 |
| 2015-07-31 |
$8 |
| 2015-04-30 |
$-3 |
| 2015-01-31 |
$-4 |
| 2014-10-31 |
$-4 |
| 2014-07-31 |
$-3 |
| 2014-04-30 |
$-0 |
| 2014-01-31 |
$-4 |
| 2013-10-31 |
$-3 |
| 2013-07-31 |
$-3 |
| 2013-04-30 |
$-6 |
| 2013-01-31 |
$-6 |
| 2012-10-31 |
$-4 |
| 2012-07-31 |
$-27 |
| 2012-04-30 |
$-3 |
| 2012-01-31 |
$-4 |
| 2011-10-31 |
$-4 |
| 2011-07-31 |
$-4 |
| 2011-04-30 |
$-2 |
| 2011-01-31 |
$-6 |
| 2010-10-31 |
$-1 |
| 2010-07-31 |
$-6 |
| 2010-04-30 |
$-5 |
| 2010-01-31 |
$-10 |
| 2009-10-31 |
$-2 |
| 2009-07-31 |
$-5 |
| 2009-04-30 |
$-4 |
| 2009-01-31 |
$-8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.106B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
